This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, X. Q. Articles by Poon, R. Y. C. Search for Related Content PubMed PubMed Citation Articles by Wang, X. Q. Articles by Poon, R. Y. C.

A Possible Role of p73 on the Modulation of p53 Level through MDM2¹

Department of Biochemistry, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong [X. Q. W., A. W. S. L., K. M. L., R. Y. C. P.], and Division of Otolaryngology, Department of Surgery, University of California, San Diego, La Jolla, California 92103 [W. M. O.]

MDM2, one of the transcriptional targets of p53, can target p53 for degradation in a negative feedback loop. The p53-related protein p73, however, can bind to MDM2 but is not consequently down-regulated. Here we demonstrate that p73 could transactivate the MDM2 promoter in p53-null cell lines. In p53-null cell lines, the level of MDM2 was increased by p73 due to increases in transcription and protein stability of MDM2. In transient transfection assays, inhibition of the transcriptional activity of p73 required a higher amount of MDM2 than that of p53. This is probably due to the fact that MDM2 can target p53, but not p73, for degradation. We demonstrated further that the level of p53 could be altered by a cooperation between MDM2 and p73, but not by transcriptional inactive mutants of p73. Expression of p73 resulted in a reduction of the ectopically expressed p53 in transient transfections or of the endogenous p53 induced by Adriamycin- or UV-mediated damage. These reductions of p53 were likely to be due to an increase in MDM2-mediated proteolysis. These results suggest the possibility that different levels of p73 in the cell may act as a mechanism to modulate p53 responses after DNA damage and other stresses and that an increase rather than a decrease in p73 may play a role in tumorigenesis.

This article has been cited by other articles:

				X. Chen, E. M. Sturgis, A. K. El-Naggar, Q. Wei, and G. Li Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers Carcinogenesis, November 1, 2008; 29(11): 2120 - 2125. [Abstract] [Full Text] [PDF]

				Y. Ge, J. S. Byun, P. De Luca, G. Gueron, I. M. Yabe, S. G. Sadiq-Ali, W. D. Figg, J. Quintero, C. M. Haggerty, Q. Q. Li, et al. Combinatorial Antileukemic Disruption of Oxidative Homeostasis and Mitochondrial Stability by the Redox Reactive Thalidomide 2-(2,4-Difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and Flavopiridol Mol. Pharmacol., September 1, 2008; 74(3): 872 - 883. [Abstract] [Full Text] [PDF]

				W. M. Chan and R. Y.C. Poon The p53 Isoform {Delta}p53 Lacks Intrinsic Transcriptional Activity and Reveals the Critical Role of Nuclear Import in Dominant-Negative Activity Cancer Res., March 1, 2007; 67(5): 1959 - 1969. [Abstract] [Full Text] [PDF]

				G. Li, X. Zhai, Z. Zhang, R. M. Chamberlain, M. R. Spitz, and Q. Wei MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis Carcinogenesis, October 1, 2006; 27(10): 2028 - 2033. [Abstract] [Full Text] [PDF]

				J. V. Thottassery, L. Westbrook, H. Someya, and W. B. Parker c-Abl-independent p73 stabilization during gemcitabine- or 4'-thio-{beta}-D-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells. Mol. Cancer Ther., February 1, 2006; 5(2): 400 - 410. [Abstract] [Full Text] [PDF]

				W. H. Toh, S. Kyo, and K. Sabapathy Relief of p53-mediated Telomerase Suppression by p73 J. Biol. Chem., April 29, 2005; 280(17): 17329 - 17338. [Abstract] [Full Text] [PDF]

				G. Li, L.-E Wang, R. M. Chamberlain, C. I. Amos, M. R. Spitz, and Q. Wei p73 G4C14-to-A4T14 Polymorphism and Risk of Lung Cancer Cancer Res., October 1, 2004; 64(19): 6863 - 6866. [Abstract] [Full Text] [PDF]

				G. Li, E. M. Sturgis, L.-E. Wang, R. M. Chamberlain, C. I. Amos, M. R. Spitz, A. K. El-Naggar, W. K. Hong, and Q. Wei Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck Carcinogenesis, October 1, 2004; 25(10): 1911 - 1916. [Abstract] [Full Text] [PDF]

				U. M. Moll and N. Slade p63 and p73: Roles in Development and Tumor Formation Mol. Cancer Res., July 1, 2004; 2(7): 371 - 386. [Abstract] [Full Text] [PDF]

				W. M. Chan, W. Y. Siu, A. Lau, and R. Y. C. Poon How Many Mutant p53 Molecules Are Needed To Inactivate a Tetramer? Mol. Cell. Biol., April 15, 2004; 24(8): 3536 - 3551. [Abstract] [Full Text] [PDF]

				K. Onel and C. Cordon-Cardo MDM2 and Prognosis Mol. Cancer Res., January 1, 2004; 2(1): 1 - 8. [Abstract] [Full Text] [PDF]

				K. M. Leung, L. S. Po, F. C. Tsang, W. Y. Siu, A. Lau, H. T. B. Ho, and R. Y. C. Poon The Candidate Tumor Suppressor ING1b Can Stabilize p53 by Disrupting the Regulation of p53 by MDM2 Cancer Res., September 1, 2002; 62(17): 4890 - 4893. [Abstract] [Full Text] [PDF]

				M. S. Irwin and W. G. Kaelin p53 Family Update: p73 and p63 Develop Their Own Identities Cell Growth Differ., July 1, 2001; 12(7): 337 - 349. [Full Text] [PDF]